Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring
European Journal of Clinical Pharmacology · 2026
DOI: 10.1007/s00228-026-04141-4 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Clinical Pharmacology, 2026. Verfasst von Canan Akman und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, Canakkale Onsekiz Mart University, Canakkale, Türkiye. Hauptthemen laut MEDLINE: Long QT Syndrome, Electrocardiography, Arrhythmias, Cardiac, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 92 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The electrocardiogram (ECG) remains the foremost non-invasive tool for detecting adverse drug effects on cardiac electrophysiology, encompassing QT interval prolongation, torsades de pointes (TdP), atrioventricular (AV) block, and sodium-channel-mediated QRS widening. As polypharmacy becomes ubiquitous - particularly in ageing populations and oncology - clinicians require a structured understanding of drug-ECG interactions to mitigate sudden cardiac death risk. METHODS: A systematic narrative review was conducted using PubMed, Embase, and the Cochrane Library covering January 2006 to April 2026. Priority was given to meta-analyses, systematic reviews, scientific statements, and guidelines addressing drug-induced ECG changes, QTc measurement methodology, TdP risk stratification, and ECG monitoring protocols. Reference lists of key papers were hand-searched. Seventy references meeting quality and relevance criteria are cited. RESULTS: Numerous drug classes - including antiarrhythmics, antibiotics, antipsychotics, antidepressants, antiemetics, and oncology agents - prolong the corrected QT interval primarily through blockade of the cardiac hERG/IKr potassium channel. Modifiable risk factors include hypokalaemia, hypomagnesaemia, bradycardia, and co-prescription of CYP3A4 inhibitors. Female sex, age ≥ 65 years, congenital long QT syndrome carriers, and cardiac failure patients are at disproportionate TdP risk. The validated Tisdale Risk Score enables pre-treatment stratification in hospitalised patients. Drug-specific ECG monitoring protocols with actionable thresholds are summarised. CONCLUSIONS: Drug-induced ECG changes are common, clinically consequential, and often preventable. Evidence-based monitoring protocols, correction of modifiable risk factors, and prompt recognition of ominous ECG patterns substantially reduce adverse outcomes. Prescriber education across all clinical settings is imperative.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Emergency Medicine, Canakkale Onsekiz Mart University, Canakkale, Türkiye.
- Department of Emergency Medicine, Marmara University School of Medicine, Pendik, Istanbul, Türkiye.
- Department of Emergency Medicine, Istanbul Beykent University, Istanbul, Türkiye.
- Department of Emergency Medicine, University of Health Sciences, Istanbul Education and Research Hospital, Fatih, Istanbul, PK 34098, Türkiye.
- Department of Emergency Medicine, Meram State Hospital, Konya, Türkiye.
- Department of Emergency Medicine, Onyedi Eylul University, Bandırma Training and Research Hospital, Balıkesir, Türkiye.
Zitieren
APA
Akman, C., Ucar, A. B., Girgin, M. C., Erdem, B., Yilmaz, G., Beyoglu, R., & Karcioglu, O. (2026). Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-026-04141-4
Vancouver
Akman C, Ucar AB, Girgin MC, Erdem B, Yilmaz G, Beyoglu R, et al. Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring. European Journal of Clinical Pharmacology. 2026. doi:10.1007/s00228-026-04141-4
BibTeX
@article{Akman2026,
author = {Akman, Canan and Ucar, Asli Bahar and Girgin, Mehmet Can and Erdem, Busra and Yilmaz, Gokhan and Beyoglu, Resad and Karcioglu, Ozgur},
title = {Electrocardiographic identification of drug effects: QT prolongation, arrhythmias, and clinical monitoring},
journal = {European Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1007/s00228-026-04141-4}
}
EUVIMED